Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson and Apple to Study If Apple Watches Can Reduce Stroke Risk in Seniors

By David Jagielski – Feb 25, 2020 at 5:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The companies are taking volunteers for a clinical trial to see if the wearable devices can identify a common stroke precursor.

Johnson & Johnson (JNJ -0.71%) and Apple (AAPL -3.00%) are inviting people 65 and older to participate in what they describe as a "landmark clinical trial." Their Heartline Study will utilize the heart-health monitoring features of the Apple Watch to see if the information the wearable device gathers can be useful in detecting atrial fibrillation (AFib) -- an irregular heart rhythm that can lead to stroke. 

As Johnson & Johnson VP of Medical Affairs Dr. Paul Burton notes, "AFib can potentially lead to more strokes for people over the age of 65. Cases are more common." One feature of the Apple Watch is that it tracks the wearer's heart rate and can notify them when it's unusually high or low. Watch owners commonly use them to track their daily activity levels, monitor their workouts, and record how many calories they've burned. 

The companies originally announced their plans for this study last year; now, they are ready to start accepting participants. People interested in being part of the study will need to have a traditional fee-for-service Medicare plan as well as an iPhone that is model 6s or newer. The study will track participants for at least two years.

Monitoring heart rate on a watch.

Image source: Getty Images.

According to research company Strategy Analytics, 31 million Apple Watches shipped in 2019 -- more than all Swiss watch brands shipped combined -- 21 million. In further evidence of the overwhelming popularity of the devices, shipments of the tech company's Watch grew 36% last year, while those of Swiss watches declined by 13%.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Apple Inc. Stock Quote
Apple Inc.
AAPL
$138.20 (-3.00%) $-4.28
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$163.36 (-0.71%) $-1.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.